Search
Toggle theme
Menu
Back
Home
Publications
Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
Public
More options
Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
N
Shared by
NobleBlocks
on Sep 30, 2014 • 12:00 AM UTC
Authors:
R. Henry
,
J. Rosenstock
,
S. Edelman
+7 more
Download PDF
Share
Summary
Sum
PDF
Figures
Figs
Discrepancies
Disc
EDDII
Article
Art
Subject
Medicine
Finding related papers...
Discussions
(0)
Add Comment
No comments yet
Be the first to share your thoughts!
Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study | NobleBlocks
